Tarsus Pharmaceuticals Reports Third Quarter 2026 Financial Results

Tarsus Pharmaceuticals reported third-quarter 2026 net product sales of $194.6 million, above analyst estimates of $187.8 million, with XDEMVY sales up 64% year over year. The company posted a net loss of $668.3 million, largely reflecting $632.2 million in acquired in-process research and development expenses tied to recent pipeline acquisitions. Tarsus completed enrollment in the Phase 2 Calliope trial of TP-05 and expects to begin the Phase 3 Comfort study of IRX-101 and report topline Phase 2 Kore trial data for TP-04 in the first half of 2027.